8 December 2022 in JCI Insight
Glycogen debranching enzyme deficiency in glycogen storage disease type III (GSD III) results in excessive glycogen accumulation in multiple tissues, primarily the liver, heart, and skeletal muscle. We recently reported that an adeno-associated virus vector expressing a bacterial debranching enzyme (pullulanase) driven by the ubiquitous CMV enhancer/chicken β-actin (CB) promoter cleared glycogen in major affected tissues of infant GSD IIIa mice. In this study, we developed a potentially novel dual promoter consisting of a liver-specific promoter (LSP) and the CB promoter for gene therapy in adult GSD IIIa mice. Ten-week treatment with an adeno-associated virus vector containing the LSP-CB dual promoter in adult GSD IIIa mice significantly increased pullulanase expression and reduced glycogen contents in the liver, heart, and skeletal muscle, accompanied by the reversal of liver fibrosis, improved muscle function, and a significant decrease in plasma biomarkers alanine aminotransferase, aspartate aminotransferase, and creatine kinase. Compared with the CB promoter, the dual promoter effectively decreased pullulanase-induced cytotoxic T lymphocyte responses and enabled persistent therapeutic gene expression in adult GSD IIIa mice. Future studies are needed to determine the long-term durability of dual promoter–mediated expression of pullulanase in adult GSD IIIa mice and in large animal models.
1 December 2017 in Molecular Therapy - Methods & Clinical Development
2 January 2026 in EBioMedicine
Pompe disease (PD), caused by acid α-glucosidase (GAA) deficiency, leads to glycogen accumulation in various tissues including the central nervous system. While enzyme replacement therapy (ERT) is lifesaving, it does not cross the blood-brain barrier. CNS manifestations including sensorineural hearing loss, dysarthria, and cognitive delay-persist despite ERT. Hence, CNS-specific biomarkers are needed to identify at-risk patients and guide monitoring and treatment. This clinical, retrospective study evaluated the utility of plasma glial fibrillary acidic protein (GFAP) as a potential biomarker of CNS involvement in infantile-onset Pompe disease (IOPD) compared to plasma neurofilament light chain (NfL). Plasma GFAP and NfL levels were measured longitudinally in 37 patients with PD (180 samples, ages 0.1-21 years) and 54 age- and sex-matched controls. Patients were grouped as (1) IOPD with severe neurologic involvement (n = 7), (2) IOPD with attenuated neurologic involvement (n = 13), and (3) late-onset PD without neurologic involvement (LOPD; n = 17). Neurologic status was determined via clinical examination and/or brain MRI white matter grading via Modified Fazekas Scores (MFS). GFAP levels were highest in IOPD patients with severe neurologic involvement. Patients with IOPD in the attenuated neurologic involvement group had, on average, lower plasma GFAP concentrations than those with severe neurologic involvement but greater GFAP levels than patients with LOPD, which resembled controls. GFAP outperformed NfL in differentiating patients with IOPD from controls (AUC = 0.886 vs 0.705) and identifying severe from attenuated neurologic involvement group (AUC = 0.801 vs 0.745). NfL showed high variability between controls and PD subgroups. Plasma GFAP levels reliably reflect CNS disease burden in IOPD and outperform NfL in diagnostic performance. GFAP may be a useful biomarker for detecting and monitoring CNS involvement in PD. Funding was provided in part by Sanofi (Cambridge, Massachusetts, USA). Philanthropic support was provided in part by Judy and Monty Frost, Abigail and JB Spaulding, AG Cox Charity Trust and Macie's Mission.
14 November 2025 in Science Advances
Glycogen storage disease (GSD) type IX γ2 is a rare inborn error of metabolism where a defect in glycogenolysis leads to the inability to break down glycogen in the liver. Patients with GSD IX γ2 develop hypoglycemia and advanced liver disease, placing them at risk for liver transplantation. This study evaluates the efficacy of liver-directed AAV gene therapy in a murine model of GSD IX γ2.
Phkg2
−/−
mice underwent treatment with AAV gene therapy (AAV9-LSP- mPhkg2 , 5 × 10 12 vg/kg, intravenous delivery) at ages 3 or 6 months and were treated for either 2 weeks, 3 months, or 12 months. Results demonstrated that AAV gene therapy reduced GSD IX γ2 disease burden across all primary end points. AAV gene therapy also persisted across the mouse lifespan and reduced preexisting liver fibrosis. This work provides preclinical data supporting AAV gene therapy as a definitive treatment for GSD IX γ2.
1 December 2024 in Annals of Translational Medicine
Expanding therapeutic options for Pompe disease: a new small molecule inhibitor of glycogen synthase 1 (GYS1) shows preclinical promise in Pompe disease